In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories. Together, they discuss recent news about virus activity and explore the value of collaboration in shaping innovative diagnostic strategies.

Recognize the motivations and barriers of first-time blood donors and work to retain them for sustainable future donations.

Mayo Clinic Laboratories' specimen pickup and delivery schedules will be altered due to the upcoming Thanksgiving holiday. To ensure specimen stability and prevent delays, follow the guidelines outlined below for domestic clients and international clients.

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

Join us for Mayo Clinic Laboratories Education first-ever virtual phlebotomy workshop on Wednesday, Oct. 1.

PACE/State of FL - Presentation Recording Coming Soon - This presentation explores the distinctions between capillary and venous collection and compares home-based versus clinic-based sampling, with attention to delayed processing and shipping stability. 

Clinically relevant overview of key genetic factors, testing strategies, and post-result care.

Conflict is a natural part of human interaction, and the workplace is not immune from that experience.  Through this microlearning, we'll explore how proper conflict[...]

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, share insights from industry news and recent conferences, including PlatforMed.

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

For healthcare professionals seeking to enhance their understanding of the assessment and treatment options for patients with neurodegenerative diseases.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by colleagues Ellen Dijkman Dulkes and Brianne Newton. They discuss common reasons that outreach programs fail to launch and strategies for building momentum to implement a program.

The increased prevalence of certain tick- and mosquito-borne illnesses, the benefits of an algorithmic testing approach, and the growing importance of co-infection testing.

On Tuesday, June 24, the mayocliniclabs.com website will feature a refreshed homepage. Incorporating valuable feedback from users, the site has been redesigned it to highlight the most frequently used features and content. The aim to enhance user experience with a more intuitive, visually appealing, and responsive website. These new features will make it easier to find information and complete tasks.

John Lieske, M.D., and Sandra Taler, M.D., explain how Mayo Clinic Laboratories' mass spectrometry assay helps evaluate patients for resistant hypertension. The test can detect antihypertensive medications in urine, providing evidence of whether patients are actually absorbing their medications or whether a new approach might be needed.